Benlysta could become first new lupus drug in decades after FDA panel endorsement
This article was originally published in Scrip
Executive Summary
Human Genome Sciences (HGS) won strong support from the US FDA's arthritis advisory committee for marketing approval for its biologic Benlysta (belimumab) as adjunctive therapy for systemic lupus erythematosus (SLE), despite committee members not being overwhelmed by its efficacy.